Pentavalent Meningococcal Conjugate Vaccine

Award type :
Product Development Award (Bridging Award)

Product type :
Vaccines

Award year :
2023

Project start date :
01 / 30 / 2023

Project end date :
10 / 31 / 2024

Project duration (months) :
21

Development stage :
Phase 1, Phase 2, Phase 3

Target disease :
Meningitis

Region served :
Sub-Saharan Africa

Recipient organization / Country of funding recipient organization :
Eubiologics / Republic of Korea

Collaborator(s) / Country :
Program for Appropriate Technology in Health (PATH) / USA

Funding amount(KRW) :
2,696,033,970

Subsequent Project :
🔗Pentavalent Meningococcal Conjugate vaccine (BA 2)

This grant aims to develop and obtain WHO PQ for an affordable NmCV-5 vaccine for infants through adults, creating a second supplier to enhance supply security and competitive pricing, in line with the Defeating Meningitis by 2030 Global Road Map. EuBiologics’ NmCV-5 is expected to provide durable
immunity against all five serogroups, offering direct protection and contributing to herd immunity. Key goals include conducting comprehensive Phase II/III clinical trials in Africa to evaluate safety, immunogenicity, and lot-to-lot consistency compared to a licensed multivalent conjugate vaccine for individuals aged 9 months to 29 years. The vaccine is designed for ease of storage, handling, and administration. Countries in the Sub-Saharan African Meningitis Belt will benefit from enhanced supply security and improved affordability. A Phase I study was conducted in South Korea with clinical trial material produced for Phase II/III studies.